An Analysis of the Use of Systemic Antifungals (Fluconazole, Itraconazole, and Terbinafine) in Galicia, Spain, between 2019 and 2022
Abstract
:1. Introduction
2. Materials and Methods
3. Results and Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Arana Zumaquero, M.; Vallejo Hernández, R.; Ortega Polar, E.; Gómez González del Tánago, P.; Panadero Carlavilla, F.J. Infeciones micóticas de la piel. Panor. Actual Med. 2020, 44, 1066–1074. [Google Scholar]
- Jenks, J.D.; Cornely, O.A.; Chen, S.C.A.; Thompson, G.R.; Hoenigl, M. Breakthrough Invasive Fungal Infections: Who Is at Risk? Mycoses 2020, 63, 1021–1032. [Google Scholar] [CrossRef] [PubMed]
- Fallas-Mora, A.; Díaz-Madriz, J.P.; Chaverri-Fernández, J.M.; Zavaleta-Monestel, E. Evaluation of Systemic Antifungal Use in a Latin American General Care Hospital: A Retrospective Study. Pharmacy 2023, 11, 108. [Google Scholar] [CrossRef] [PubMed]
- Base de Datos del Conocimiento Sanitario Bot PLUS 2.0. Available online: https://botplusweb.portalfarma.com/ (accessed on 29 August 2023).
- Fisher, M.C.; Alastruey-Izquierdo, A.; Berman, J.; Bicanic, T.; Bignell, E.M.; Bowyer, P.; Bromley, M.; Brüggemann, R.; Garber, G.; Cornely, O.A.; et al. Tackling the emerging threat of antifungal resistance to human health. Nat. Rev. Microbiol. 2022, 20, 557–571. [Google Scholar] [CrossRef] [PubMed]
- Perlin, D.S.; Rautemaa-Richardson, R.; Alastruey-Izquierdo, A. The global problem of antifungal resistance: Prevalence, mechanisms, and management. Lancet Infect. Dis. 2017, 17, e383–e392. [Google Scholar] [CrossRef]
- Hendrickson, J.A.; Hu, C.; Aitken, S.L.; Beyda, N. Antifungal Resistance: A Concerning Trend for the Present and Future. Curr. Infect. Dis. Rep. 2019, 21, 47. [Google Scholar] [CrossRef]
- McEwen, S.A.; Collignon, P.J. Antimicrobial Resistance: A One Health Perspective. Microbiol. Spectr. 2018, 6, 2. [Google Scholar] [CrossRef]
- Fletcher, S. Understanding the contribution of environmental factors in the spread of antimicrobial resistance. Environ. Health Prev. Med. 2015, 20, 243–252. [Google Scholar] [CrossRef]
- Brown, G.D.; Denning, D.W.; Gow, N.A.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden killers: Human fungal infections. Sci. Transl. Med. 2012, 4, 165rv13. [Google Scholar] [CrossRef]
- Rahme, D.; Ayoub, M.; Shaito, K.; Saleh, N.; Assaf, S.; Lahoud, N. First trend analysis of antifungals consumption in Lebanon using the World Health Organization collaborating center for drug statistics methodology. BMC Infect. Dis. 2022, 22, 882. [Google Scholar] [CrossRef]
- Pakyz, A.L.; Gurgle, H.E.; Oinonen, M.J. Antifungal use in hospitalized adults in US academic health. Am. J. Health-Syst. Pharm. 2011, 68, 415–418. [Google Scholar] [CrossRef] [PubMed]
- Zarb, P.; Amadeo, B.; Muller, A.; Drapier, N.; Vankerckhoven, V.; Davey, P.; Goossens, H.; ESAC-3 hospital care subproject group. Antifungal therapy in European hospitals: Data from the ESAC point-prevalence surveys 2008 and 2009. Clin. Microbiol. Infect. 2012, 18, E389–E395. [Google Scholar] [CrossRef] [PubMed]
- Gross, B.N.; Steib-Bauert, M.; Kern, W.V.; Knoth, H.; Borde, J.P.; Krebs, S.; Hug, M.J.; Rothe, U.; Maier, L.; de With, K. Hospital use of systemic antifungal drugs: A multi-center surveillance update from Germany. Infection 2015, 43, 423–429. [Google Scholar] [CrossRef] [PubMed]
- Meyer, E.; Schwab, F.; Gastmeier, P.; Ruden, H.; Heininger, A. Antifungal use in intensive care units. J. Antimicrob. Chemother. 2007, 60, 619–624. [Google Scholar] [CrossRef]
- Bassetti, M.; Ansaldi, F.; Nicolini, L.; Malfatto, E.; Molinari, M.P.; Mussap, M.; Rebesco, B.; Bobbio Pallavicini, F.; Icardi, G.; Viscoli, C. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J. Antimicrob. Chemother. 2009, 64, 625–629. [Google Scholar] [CrossRef]
- Massanet, P.; Corne, P.; Conseil, M.; Perrigault, P.F.; Lachaud, L.; Jaber, S.; Calvet, B.; Jonquet, O.; Reynes, J. Antifungal treatments of candidemia in non-neutropenic patients: Evaluation of practice in intensive care units. Med. Mal. Infect. 2010, 40, 644–649. [Google Scholar] [CrossRef] [PubMed]
- Fournier, P.; Schwebel, C.; Maubon, D.; Vesin, A.; Lebeau, B.; Foroni, L.; Hamidfar-Roy, R.; Cornet, M.; Timsit, J.F.; Pelloux, H. Antifungal use influences Candida species. Distribution and susceptibility in the intensive care unit. J. Antimicrob. Chemother. 2011, 66, 2880–2886. [Google Scholar] [CrossRef]
- Alfandari, S.; Bonenfant, C.; Depretere, L.; Beaucaire, G. Use of 27 parenteral antimicrobial agents in north of France hospitals. Med. Mal. Infect. 2007, 37, 103–107. [Google Scholar] [CrossRef]
- Meyer, E.; Schwab, F.; Gastmeier, P.; Rueden, H.; Daschner, F.D. Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): A summary of the data from 2001 through 2004. Infection 2006, 34, 303–309. [Google Scholar] [CrossRef]
- Pakyz, A.L.; MacDougall, C.; Oinonen, M.; Polk, R.E. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med. 2008, 168, 2254–2260. [Google Scholar] [CrossRef]
- Benedict, K.; Tsay, S.V.; Bartoces, M.G.; Vallabhaneni, S.; Jackson, B.R.; Hicks, L.A. Outpatient Antifungal Prescribing Patterns in the United States, 2018. Antimicrob. Steward. Healthc. Epidemiol. 2022, 1, e6. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Van Driel, M.L.; McGuire, T.M.; Hollingworth, S.A. Trends in Systemic Antifungal Use in Australia, 2005–2016: A Time-Series Analysis. Jpn. J. Infect. Dis. 2022, 75, 254–261. [Google Scholar] [CrossRef]
- Valladales-Restrepo, L.F.; Ospina-Cano, J.A.; Aristizábal-Carmona, B.S.; López-Caicedo, D.F.; Toro-Londoño, M.; Gaviria-Mendoza, A.; Machado-Duque, M.E.; Machado-Alba, J.E. Study of Prescription-Indication of Outpatient Systemic Anti-Fungals in a Colombian Population. A Cross-Sectional Study. Antibiotics 2022, 11, 1805. [Google Scholar] [CrossRef]
- Fondevilla, E.; Grau, S.; Mojal, S.; Palomar, M.; Matas, L.; Gudiol, F. Consumption of systemic antifungal agents among acute care hospitals in Catalonia (Spain), 2008–2013. Expert. Rev. Anti-Infect. Ther. 2016, 14, 137–144. [Google Scholar] [CrossRef] [PubMed]
- Olaechea-Astigarraga, P.M.; Álvarez-Lerma, F.; Palomar-Martínez, M.; Insausti-Ordeñana, J.; López-Pueyo, M.J.; Seijas-Betolaza, I.; Otal-Entraigas, J.J.; Gimeno-Costa, R.; Gracia-Arnillas, M.P.; Grupo ENVIN-HELICS. Trends in systemic antifungaluse in critically ill patients. Multicenter observational study, 2006–2010. Enfermedades Infecc. Y Microbiol. Clin. 2012, 30, 435–440. [Google Scholar] [CrossRef]
- March Rosselló, G.A.; Mora, A.A.; Pérez Rubio, A.; Eiros Bouza, J.M. Antiinfectives for systemic use prescribed in a Spanish hospital between 2009–2013. Infez. Med. 2016, 24, 18–23. [Google Scholar] [PubMed]
- Vázquez-Prieto, S.; Vaamonde, A.; Paniagua, E. Study of the Use of Antinematode Drugs, Mebendazole and Pyrantel, in Galicia (Spain) from 2016 to 2020. J. Parasitol Res. 2022, 13, 7792006. [Google Scholar] [CrossRef]
- Vázquez-Prieto, S.; Vaamonde, A.; Paniagua, E. Study of the Use of Permethrin 5% Cream in Galicia (Spain) between 2018 and 2021. Infect. Dis. Rep. 2023, 15, 222–230. [Google Scholar] [CrossRef]
- Instituto Gallego de Estadística. Available online: https://www.ige.eu/igebdt/selector.jsp?COD=590&paxina=001&c=0201001002 (accessed on 1 August 2023).
- Sanchez, M.L.; Vallina-Victorero, M.J.; Bachiller, M.R.; Arbizu, R.; Llaneza, E.; Rozada, S.; Eiros, J.M. Variability in the community consumption of antibiotics: A problem in Europe, Spain and Asturias. Infez Med. 2019, 27, 134–140. [Google Scholar]
- Bongomin, F.; Gago, S.; Oladele, R.O.; Denning, D.W. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J. Fungi 2017, 3, 57. [Google Scholar] [CrossRef]
- Antimicrobial Resistance. Available online: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (accessed on 29 August 2023).
- WHO. Introduction to Drug Utilization Research; World Health Organization: Oslo, Norway, 2003. [Google Scholar]
- Laporte, J.R.; Tognoni, G. Estudios de utilización de medicamentos y farmacovigilancia. In Principios de Epidemiología del Medicamento, 1st ed.; Laporte, J.R., Tognoni, G., Eds.; Masson-Salvat: Barcelona, Spain, 1993; pp. 1–24. [Google Scholar]
- Figueiras, A.; Caamano, F.; Gestal Otero, J. Metodología de los estudios de utilización de medicamentos en atención primaria. Gac. Sanit. 2000, 14, 7–19. [Google Scholar]
- Capellá, D.; Laporte, J.R. Métodos Aplicados en Estudios Descriptivos de Utilización de Medicamentos. In Principios de Epidemiología del Medicamento, 1st ed.; Laporte, J.R., Tognoni, G., Eds.; Masson-Salvat: Barcelona, Spain, 1993; pp. 67–94. [Google Scholar]
- Çağlar, İ.; Devrim, İ.; Özdemir, H.; Şahbudak, Z.; Sönmez, G.; Buyukcam, A.; Gulhan, B.; Kara, A.; Aygun, D.F.; Bayram, N.; et al. Antifungal consumption, indications and selection of antifungal drugs in paediatric tertiary hospitals in Turkey: Results from the first national point prevalence survey. J. Glob. Antimicrob. Resist. 2018, 15, 232–238. [Google Scholar] [CrossRef] [PubMed]
- Pathadka, S.; Yan, V.K.C.; Neoh, C.F.; Al-Badriyeh, D.; Kong, D.C.M.; Slavin, M.A.; Cowling, B.J.; Hung, I.F.N.; Wong, I.C.K.; Chan, E.W. Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries. Drugs 2022, 82, 1193–1205. [Google Scholar] [CrossRef]
- Hamim, H.; Sangeda, R.Z.; Bundala, M.; Mkumbwa, S.; Bitegeko, A.; Sillo, H.B.; Fimbo, A.M.; Chambuso, M.; Mbugi, E.V. Utilization Trends of antiviral and antifungal agents for human systemic use in Tanzania from 2010 to 2017 using the World Health Organization collaborating Centre for Drug Statistics Methodology. Front. Trop. Dis. 2021, 7, 30. [Google Scholar] [CrossRef]
- Denning, D.W.; Kneale, M.; Sobel, J.D.; Rautemaa-Richardson, R. Global burden of recurrent vulvovaginal candidiasis: A systematic review. Lancet Infect Dis. 2018, 18, e339–e347. [Google Scholar] [CrossRef]
- Downloadable Tables for the Report, Antimicrobial Consumption in the EU/EEA (ESAC-Net)—Annual Epidemiological Report for 2021. Available online: https://www.ecdc.europa.eu/en/publications-data/downloadable-tables-antimicrobial-consumption-annual-epidemiological-report-2021 (accessed on 20 December 2023).
- Adriaenssens, N.; Coenen, S.; Versporten, A.; Muller, A.; Vankerckhoven, V.; Goossens, H.; ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): Quality appraisal of antibiotic use in Europe. J. Antimicrob. Chemother. 2011, 66, 71–77. [Google Scholar] [CrossRef]
- Senent Sánchez, C.J.; Tapia de Pedro, G. La alergia a la humedad: Los hongos ¿qué son y cómo evitarlos? In El Libro de las Enfermedades Alérgicas, 2nd ed.; Zubeldia, J.M., Baeza, M.L., Chivato, T., Jáuregui, I., Senent, C.J., Eds.; Fundación BBVA: Bilbao, Spain, 2021; pp. 103–111. [Google Scholar]
- Vallabhaneni, S.; Baggs, J.; Tsay, S.; Srinivasan, A.R.; Jernigan, J.A.; Jackson, B.R. Trends in antifungal use in US hospitals, 2006–2012. J. Antimicrob. Chemother 2018, 73, 2867–2875. [Google Scholar] [CrossRef]
- Fleming-Dutra, K.E.; Hersh, A.L.; Shapiro, D.J.; Bartoces, M.; Enns, E.A.; File, T.M., Jr.; Finkelstein, J.A.; Gerber, J.S.; Hyun, D.Y.; Linder, J.A.; et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011. JAMA 2016, 315, 1864–1873. [Google Scholar] [CrossRef]
- Ministerio de Sanidad Consumo y Bienestar Social. Plan Nacional Frente a las Resistencias Antibióticos (PRAN). Programas de Optimización de Uso de Antibióticos (PROA). 2017. Available online: https://www.resistenciaantibioticos.es (accessed on 19 December 2023).
- Comisión Galega para o Control das Resistencias Antimicrobianas. Informe da Situación en Galicia do Plan Nacional Frente á Resistencia dos Antibióticos. Available online: https://www.sergas.es/Saude-publica/Documents/884/Comisi%C3%B3n%20galega%20control%20RAM.pdf (accessed on 19 December 2023).
- Antimicrobial Consumption Dashboard (ESAC-Net). Available online: https://www.ecdc.europa.eu/en/antimicrobial-consumption/surveillance-and-disease-data/database (accessed on 21 September 2023).
Province | Fluconazole | Itraconazole | Terbinafine |
---|---|---|---|
A CORUÑA | 0.121 | 0.186 | 0.3 |
LUGO | 0.122 | 0.172 | 0.192 |
OURENSE | 0.131 | 0.155 | 0.467 |
PONTEVEDRA | 0.141 | 0.236 | 0.387 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vázquez-Prieto, S.; Vaamonde, A.; Paniagua, E. An Analysis of the Use of Systemic Antifungals (Fluconazole, Itraconazole, and Terbinafine) in Galicia, Spain, between 2019 and 2022. Diseases 2024, 12, 22. https://doi.org/10.3390/diseases12010022
Vázquez-Prieto S, Vaamonde A, Paniagua E. An Analysis of the Use of Systemic Antifungals (Fluconazole, Itraconazole, and Terbinafine) in Galicia, Spain, between 2019 and 2022. Diseases. 2024; 12(1):22. https://doi.org/10.3390/diseases12010022
Chicago/Turabian StyleVázquez-Prieto, Severo, Antonio Vaamonde, and Esperanza Paniagua. 2024. "An Analysis of the Use of Systemic Antifungals (Fluconazole, Itraconazole, and Terbinafine) in Galicia, Spain, between 2019 and 2022" Diseases 12, no. 1: 22. https://doi.org/10.3390/diseases12010022
APA StyleVázquez-Prieto, S., Vaamonde, A., & Paniagua, E. (2024). An Analysis of the Use of Systemic Antifungals (Fluconazole, Itraconazole, and Terbinafine) in Galicia, Spain, between 2019 and 2022. Diseases, 12(1), 22. https://doi.org/10.3390/diseases12010022